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ABSTRACT
Cellular uptake of human H-ferritin loaded with 50 or 350 iron ions results in 
significant cytotoxicity on HeLa cells at submicromolar concentrations. Conversely, 
Horse Spleen Ferritin, that can be considered a model of L-cages, as it contains only 
about 10% of H subunits, even when loaded with 1000 iron ions, is toxic only at >1 
order of magnitude higher protein concentrations. We propose here that the different 
cytotoxicity of the two ferritin cages originates from the presence in H-ferritin of 
a pool of non-biomineralized iron ions bound at the ferroxidase catalytic sites of 
H-ferritin subunits. This iron pool is readily released during the endosomal-mediated 
H-ferritin internalization. 
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INTRODUCTION
Ferritin is a protein highly conserved in living 
organisms, which stores iron as a bioavailable ferric-oxide 
mineral [1–3].
In animals, the 24-meric cage structure is assembled 
from two subunits, the heavy chain (H-chain) and light 
chain (L-chain), or a mix thereof. The two distinct subunits 
share a similar fold and 53% of sequence identity, but 
differ in their ability to handle iron. H-subunits contain a 
catalytic center (ferroxidase or oxidoreductase site) where 
iron(II) is oxidized to iron(III) by dioxygen on the ms 
time scale [4]. L-subunits lack the ferroxidase site; iron 
oxidation in L-type cages occurs on a time scale of the 
order of minutes and the protein mainly provides a shell to 
maintain the ferric oxide biomineral in a soluble form [5]. 
The demineralized form of L-type ferritin 
(apoferritin) has been extensively used for drug cellular 
delivery. Encapsulation of doxorubicin [6], curcumin 
[7], cisplatin [8] and desferrioxamine B [9] are only few 
examples. The selective ability of cells to internalize 
L- and H-cages through specific receptors has been 
demonstrated, namely SCARA5 (Scavenger receptor 
class A type 5) for L-rich cages and TfR1 (Transferrin 
receptor 1) for H-rich cages [10, 11].
Based on evidence attained from both 
epidemiological and molecular studies, new insights 
are linking the presence of excess iron and altered iron 
metabolism to cancer [12]. It is well established that 
many cancer cells reprogram iron metabolism in ways 
that result in net iron influx [13]. Iron starvation can 
impair cell development and growth, whereas excessive 
iron accumulation leads to cytotoxicity, resulting from 
an over-production of free radicals. Actually, it has been 
reported that certain types of tumor cells (principally 
those with c-myc and h-ras oncogenes expression) 
appear unable to deal properly with the excess iron, as a 
consequence of ferritin and ferroportin down-regulation 
[14, 15]. 
Herein we report our observations on cell death 
triggering, based on the delivery of iron to tumor cells, by 
the administration of iron-loaded ferritins. 
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RESULTS
Iron-loaded ferritins are toxic for HeLa cells
To compare the effects of H- and L-ferritin on tumor 
cells, we sought a tumor cell model that expresses both 
TfR1 and SCARA5 receptors, such as the HeLa cells. 
This choice allowed us to compare the behavior of the two 
proteins in the same cell line. 
In literature, a plethora of nanocarriers encapsulating 
different species within the natural horse spleen cage is 
available, as recently reviewed in [16]. This cage has 
the advantage of being commercially available and can 
be considered a model of L-cages, as it contains only 
about 10% of H subunits [17]. Horse spleen nanocages 
will be referred to as HoS-ferritin, hereafter. They have 
been studied in their apo form (HoS-apoferritin), in its 
commercially available form loaded with an average of 
1000 iron ions/cage (HoS-1000), as determined by ICP-
MS, and in two forms with lower loading (namely HoS-50 
and HoS-350) for comparison with H-ferritin (see below).
Recently human H-ferritin has been proposed [6] as 
a potentially superior carrier for anticancer drug delivery 
because, given its human origin, it should not activate 
inflammatory or immunological response. Efficient 
heterologous expression methods for human H-ferritin 
(≥100 mg/L of purified protein, in our hands) [4, 18] make 
it attractive also from the economical point of view. As for 
HoS-ferritin, H-ferritin can also be loaded with variable 
amounts of iron. The first two iron ions/subunit (48 iron 
ions per cage) localize in the ferroxidase site; addition 
of more iron ions initiates the biomineralization reaction 
[4]. Here, we investigated two H-ferritin cages differently 
loaded with iron, namely: i) one containing about 50 iron 
ions per cage (H-50, hereafter), which corresponds to the 
full saturation of the 24 ferroxidase sites; ii) the other, 
containing 350 iron ions per cage (H-350, hereafter), 
which corresponds to the full saturation of ferroxidase 
sites plus initial formation of the biomineral core as 
demonstrated in the TEM images (see Supplementary 
Figure 1). As expected the iron oxide core size, determined 
by TEM image analysis, was smaller in both H-350 (3.3 ± 
0.7 nm) and HoS-350 (2.6 ± 0.2 nm) due to the lower iron 
content with respect HoS-1000 (4.4 ± 0.4 nm), whereas 
HoS-50 and H-50 didn’t show any measurable core. 
 The amount of iron internalized by HeLa cells 
upon 24 h incubation in media containing variable 
concentrations of H- and HoS-ferritin was obtained by 
ICP-MS determination of the intracellular iron content 
(Figure 1A). The relative amount of internalized iron when 
using H-350, HoS-350 and HoS-1000 roughly correlates 
with the iron loading of the two carriers. The amount of 
internalized iron after the treatment with H-50 and HoS-
50 in the 1–8 μM range was too low to be determined 
with sufficient accuracy; this finding is in line with what 
one could expect by scaling down the measured effect of 
H-350 and HoS-350 by a factor of 7 in iron concentration. 
To demonstrate that the uptake of the H-Ferritins involves 
TfR1, a competition assay was carried out treating Hela 
cells with an excess of Holo-transferrin. After 5 hours of 
cell incubation in the presence of H-350, the uptake of 
H-350 decreased by about 50 ± 8% when the concentration 
of Holo-transferrin added to the culture medium was 
20 µM (Figure 1B). Since in the literature there are not 
competitors reported for SCARA5, the specific mediation 
of HoS-Ferritin uptake has been assessed by blocking 
experiments carried out with an anti-human SCARA5 
antibody (anti-SCARA5 Ab, Figure 1C). The amount of 
iron internalized by cells treated with anti−SCARA5 Ab 
and incubated with HoS-1000 0.5 µM for 5h was 56 ± 
21% than the amount internalized by control cells, thus 
confirming that SCARA5 mediates HoS-Ferritin uptake 
in Hela cells. Moreover, in order to assess whether the 
presence of 10% of H-chains in horse spleen ferritin used 
in this study can mediate its uptake through H-Ferritin 
receptors, a further competition study was carried out by 
incubating Hela cells for 5 hours with HoS-1000 (1 µM) 
in the presence of a 20-fold excess of Holo-transferrin. 
The Holo-transferrin excess caused a non significant 
reduction (3 ± 2%) of internalized iron thus ruling out the 
involvement of TfR1 receptors in the internalization of 
HoS-Ferritin (Figure 1D). The specificity of the ferritin 
targeting system was further confirmed by incubating 
H-350 and HoS-350 with an excess of H-Apo and HoS-
Apo (Supplementary Information, Supplementary Figure 
2). A significant decrease (>50%) of the internalized iron 
was observed only in the presence of the corresponding 
H-Apo or HoS-Apo forms. Vice versa no effect has been 
detected incubating H-350 and HoS-350 with an excess of 
HoS-Apo and H-350, respectively. 
Cell viability was determined by the MTT assay 
after treatment of HeLa cells for 24 h with apo and iron-
loaded H- and HoS-ferritins. While both apo forms show 
no appreciable toxicity, a clear effect is induced by the 
iron-loaded cages (Figure 2A). Strikingly, the profiles of 
cellular cytotoxicity induced by the H- and L-cages are 
very different. The effect of HoS-1000 is almost linearly 
dependent on the protein concentration whereas the 
less loaded HoS-350 and HoS-50 showed a toxicity not 
significantly different from the apo form. On the contrary, 
treatment with either H-50 or H-350 causes an abrupt 
decrease in cellular viability, which levels off at about 50% 
viability for H-350 concentrations ≥1 μM ferritin. The 
attainment of a plateau value in cell viability for both iron-
loaded H-ferritin nanocages can be interpreted in terms 
of iron-dependent downregulation of the TfR1 receptor 
expression; a well-known process in the case of incubation 
of HeLa with an excess of holo-transferrin or Fe-citrate 
[19, 20]. A flow cytometric analysis of the expression of 
TfR1 (Supplementary Figure 3) showed that the relative 
expression of this receptor with respect to untreated Hela 
cells decreases to 58 ± 5% for cells treated with 1 μM 
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H-350 and to 75 ± 6% with 1 μM H-50, suggesting that 
also iron-loaded H-ferritins activate a downregulation 
mechanism. From the results shown in Figure 2A (lack of 
saturation effects in cytotoxicity when using HoS-1000), 
one may rule out the occurrence of an analogous iron-
dependent SCARA5 down regulation response. In spite 
of the larger intracellular iron internalization induced by 
HoS-1000 with respect to H-350 or H-50, the latter two 
are much more toxic at lower protein concentrations. As 
illustrated in Figure 2B, for a given iron concentration, 
H-350 causes significantly larger reduction in cell 
viability, suggesting a different mechanism of action 
for H- and L-cages. Noteworthy, the comparison in the 
cytotoxic effect exerted by treatment with H-50 and H-350 
is not proportional to their cage iron content. This result 
suggests that the nature of the iron ions within the cage 
(ferroxidase-bound or biomineralized) might play a role. 
In principle, one may surmise that ferroxidase-bound iron 
could be associated to the generation of toxic ROS. This 
aspect is further investigated in the following sections.
Cytoplasmic ROS production was evaluated by 
measuring 2,7-dichlorofluorescein diacetate (DCF-DA) 
emission; its fluorescence intensity directly correlates 
with the steady-state concentration of intracellular ROS. 
The treatment with 5 μM iron-loaded ferritins causes 
a modest increase in ROS production with respect to 
untreated cells and to cells treated with the apoferritins 
(Figure 2C). ROS generation by H-350 is only modestly 
higher than that of H-apo, while H-50 is indistinguishable 
from the other two, within the error. HoS-1000 induces a 
ROS production which is significantly higher than HoS−
Apo, but still less than a factor of 2 whereas HoS-350 
and HoS-50 are not significantly different. In conclusion, 
cytoplasmatic ROS production does not account for the 
striking differences in cell viability between H and L of 
Figure 2A. Consistently, at protein concentrations lower 
than 5 μM, where the H-350 and H-50 are heavily toxic 
(Figure 2A), no measurable ROS production is observed. 
Moreover, in order to discriminate between an anti-
proliferative or toxic- effect of ferritins, Hela cells have 
been incubated in the presence of H−50 (0.5 µM) or 
H−350 (0.5 µM) or L−1000 (3 µM). This treatment caused 
the death of about 30–40% of cells. Then the proliferation 
rates of the survived cells have been assessed over a 
period of 5 days. No significant difference has been noted 
between these cells and the untreated control cells (see 
Figure 1: In cell studies: iron cell uptake. (A) After 24 h incubation in the presence of increasing amounts of different ferritins, cell 
lysates were analyzed by ICP-MS to measure the amount of internalized iron, which was normalized to the total protein cellular content; (B, 
C, D) competition studies: iron uptake by Hela cells after 5 h incubation in the presence of (B) H-350 (1 µΜ) and HoS-1000 (D) with and 
without the addition of an excess of holo-transferrin (20 µM); (C) HoS-1000 0.5 µM with and without anti−SCARA5 antibody 5 mg/ml.
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Supplementary Figure 4). This finding led us to exclude 
that the reduced metabolism measured with the MTT assay 
is related to the occurrence of a reduced proliferation rate.
The role of pH and endogenous reducing agents 
on iron release 
As reported [10], TfR1-imported H-ferritin is 
initially localized in endosomes and then (in about 30 
min) is distributed in both endosome and lysosomes. 
The cytotoxic effect of H-350 in the MTT assay carried 
out in the presence of chloroquine (CHL), an agent that 
limits endosomal acidification, resulted significantly 
reduced (P = 0.0076; Figure 3A). The effect is much 
smaller in the presence of DFO mesylate, a lysosomal 
iron chelator. The opposite behavior is observed for 
HoS-1000 (Figure 3A). Degradation of HoS-cages 
encapsulating massive biomineral particles (1000 iron/
cage) gives rise to observable hemosiderin bodies [21] 
(Figure 3B). Accordingly, confocal microscopy studies 
(see Supplementary Figure 5) showed that HoS-ferritin 
was completely compartmentalized in lysosomes, 
whereas H-ferritin is only in part inside the lysosomal 
compartment. Using TfR1, H-ferritin was internalized by 
the receptor-mediated mechanism, only in part undergoing 
lysosomal degradation. Despite the much lower amount of 
delivered iron, H-ferritin appears definitively more toxic.
Mature endosomes are characterized by a low 
pH value (4.9–6.0) [22, 23]. At pH 5, only H-ferritin 
spontaneously releases iron(II), whereas at neutral pH 
the presence of reducing agents is required (Figure 4A). 
HoS-1000 is able to release iron(II) only in the presence 
of reducing agents (Figure 4B). The amounts of iron(II) 
released by H-50 and H-350 account for a total of 21 
Figure 2: In cell studies: iron toxicity. (A, B) HeLa cell viability measured by the MTT assay as a function of the concentration of the 
various ferritin forms (A) and as a function of internalized iron (B). Cell viability is expressed as percentage relative to untreated cells. Data 
are presented as mean and SD of at least three independent experiments. (C) ROS generation measured by DCF-DA fluorescence emission 
(at 529 nm) after the incubation, for 24 h, of HeLa cells with 5 µM different form ferritins. In all panels, error bars indicate the SD of the 
data. (Student’s t test. HoS-1000 vs HoS−Apo: P = 0.0002; H-350 vs apo-H: P = 0.03; H-50 vs apo-H: P = 0.24; *P < 0.05, ***P < 0.001). 
In panels A, B and C, HoS-apoferritin (HoS−Apo) and H-apoferritin (H−Apo) are represented as white circles and squares, respectively; 
HoS-1000 as orange circles, HoS-350 as blue circles, HoS-50 as green circles, H-350 as red squares and H-50 as yellow squares. In panel 
D, the bars are labelled and depicted with the same color code used in A, B and C.
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Figure 3: Iron release along the endosome/lysosome import system. (A) HeLa cell viability measured by the MTT assay after 24 
of incubation with H-350 (0.5 μM) or HoS-1000 (2.5 μM) in the absence and in the presence of DFO mesylate (150 μM) and Chloroquine 
(100 μM) **P < 0.01, Student’s t-test). (B). TEM pictures of Hela cells treated with HoS-1000. Arrows indicate representative endosomes. 
Hemosiderin bodies are observed only upon incubation with HoS-ferritin. The arrowhead signs correspond to the plasma membrane 
(×30.000, lead citrate and uranyl acetate stained).
iron/cage and 57 iron/cage, respectively. The observed 
pH dependence of iron release in vitro suggests that in 
cells H-ferritin can release its metal load at the level of 
late endosomes, but HoS-1000 does not. In lysosomes, 
pH drops down to about 4.5; the harsher conditions 
combined with the possible degradation operated by 
lysosomal hydrolases [23] may cause cage disassembly. 
Moreover, iron(III) release has been determined using 
the orange xylenol based assay [24]. Xylenol orange has 
long been known as a good chelator for the quantitative 
determination of a wide range of cations, including iron. 
It binds Fe3+, but not Fe2+, at acid pH to give a colored 
complex [24] and the reaction is not sensitive to oxygen. 
Figure 4C and 4D show that HoS-1000 releases iron(III) 
Figure 4: (A, B) Mobilization of iron(II) from 0.4 μM H-50, H-350, HoS-50. HoS-350 and HoS-1000 as a function of pH (A) and (B) 
in the presence of reducing agents (GSH 0.25 mM, pH = 7; ascorbic acid 0.25 mM, pH = 7). Samples were incubated with bipyridine 
(1 mM) under aerobic conditions. The amounts of iron(II) released by H-50 and H-350 account for a total of 21 iron/cage and 57 iron/
cage, respectively. (C, D) Mobilization of iron(III) from 0.4 μM H-50, H-350, HoS-50. HoS-350 and HoS-1000 at pH = 5 (C) and pH = 
7.4 (D). Samples were incubated with Xylenol Orange (0.25 mM) under aerobic conditions. T = 0 corresponds to the addition of ferritin 
to the solution media.
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at neutral and, in particular, at acid pH more than H-350 
and H-50, whereas the iron(III) released from HoS-350 
at acid pH is similar to H-350. While iron(III) release in 
the presence of xylenol orange seems to be proportional 
to the biomineral content, independently of the cage type, 
the release of iron(II) in the presence of 2,2′-bipyridine is 
selectively observed for H-ferritin. Organisms and cells 
keep this ferric iron in solution by secreting chelating 
agents able to bind Fe(III) more tightly than OH− and 
thus preventing the oxo-bridging of Fe(III) species that 
leads to its precipitation [25]. However, by stabilizing this 
Fe(III) state, the chelating agents set the Fe(III) reduction 
potential at a low value that prevents its participation as 
oxidant in reaction with a biologic reducing agent. This 
‘stable’ ferric iron is inert in regard to the Fe(III) reduction 
reaction associated with normal iron metabolism. 
Relaxometric characterization
Horse spleen ferritin has been proposed as a carrier 
for MRI contrast agents [26, 27]; here, we investigate the 
relaxometric properties of ferritins with different iron 
loadings. 1/T1 NMRD profiles (Figure 5A) were recorded 
for H-50, H-350, HoS−50, HoS−350 and HoS-1000. 
The profiles are only marginally affected by addition of 
deferoxamine (DFO) that it is expected to bind only the iron 
fraction possibly present on the external surface of the protein 
(Figure 5B). The profiles indicate a negligible contribution 
from externally coordinated iron ions. The higher millimolar 
relaxivities at any field shown by H-50 and, to a lower extent 
by HoS-50, suggest a paramagnetic contribution from non-
biomineralized iron (Figure 5). This contribution is less 
pronounced in H-350 and almost absent in HoS-1000. As 
reported [28], the differences in H/L ratio in ferritin cages 
determine different morphologies of the mineral core and this 
fact might influence the relaxivity profiles.
DISCUSSION
A structural biology view of different toxicity of 
H and L chains 
Recent X-ray crystallography studies have 
demonstrated that the ferroxidase site of human H-ferritin 
accommodates two iron ions, named Fe1 and Fe2, that are 
bound to few protein amino acid side chains: a bridging 
carboxylate group is provided by Glu62; Fe1 is then 
bound to His65 and monodentate Glu27; Fe2 to bidentate 
Glu107; the coordination sphere of each iron ion is 
completed by water molecules. Nearby, there are two other 
additional binding sites involving the side chains of His57, 
Glu58 and Glu62, where hydrated iron ions are bound with 
low occupancy. The emerging picture is that of a cage that 
uptakes ferrous hexa-aqua ions through the C3 channels 
and delivers them (as progressively de-hydrated ions) 
towards the ferroxidase site under the effect of attractive 
electrostatic gradient created by carboxylate residues 
[29, 30]. Given the low number of protein residues 
involved in the binding of the iron at the accessory 
binding sites and in the ferroxidase site, it is reasonable to 
propose that they could be more readily released and react. 
The Fe1 and Fe2 sites remain always populated during 
subsequent reaction turnover, while the biomineral grows. 
Their iron release upon lowering pH can be explained in 
terms of protonation of the acidic residues involved in 
their binding. In contrast, in human L-ferritin and horse 
spleen ferritin, some of us have demonstrated that the 
iron ions that enter the C3 channels and react to form the 
biomineral precursors at the nucleation sites are blocked 
within (μ3-oxo)tris[(μ2-peroxo)(μ2-glutamato-κO:κO’)] 
(glutamato-κO)(diaquo)triiron(III) clusters. So they are 
probably more stable than iron ions in the ferroxidase 
site and lose their importance when the biomineral grows 
Figure 5: Ferritins as relaxation agents. 1/T1 NMRD profiles (pH 7.4, 25° C) of H-50, H-350, HoS−50, HoS−350 and HoS-1000 
(10 µM in protein). The profiles were recorded without (A) and with the ferritins treatment with DFO 0.7 mM (15’ at 25° C) (B), to avoid 
any possible contribution from spurious surface iron ions. The relaxivity values (r1p mM
-1s-1) were normalized to the iron concentration.
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[31]. Furthermore, we can hypothesize an additional toxic 
effect due to the direct reaction of H2O2 generating OH
. 
inside the protein cavity. In fact, as reported by Zhao and 
coworkers [32], H2O2 is able to react with the ferroxidase-
bound iron(III), showing a stronger reactivity with the 
µ-oxo diferric complex than with the Fe(III) core which is 
more thermodynamically stable (in particular in the case 
of L-ferritin). The reactivity is inversely proportional to 
the size of the Fe(III) core. 
Therefore, the higher H-ferritin toxicity 
originates from its peculiar iron cargo as well by 
its pathway of interaction with the ELC
 The characteristic behavior observed for H-ferritin, 
which shows toxicity effects that are not proportional 
to the iron-load, suggests a different behavior for the 
biomineralized caged iron and the “mobile” iron pool 
constituted by those metal ions that are at the relatively 
weakly binding ferroxidase sites and low-populated 
accessory binding sites in the catalytic center [4, 29, 
33]. Indeed, the observed effects can be accounted for as 
originating by a pool of about 50 iron/cage over a total of 
350/cage. Moreover the reduced acidification capacity of 
the ELC obtained by the treatment with CHL significantly 
reduces the H- but not HoS-ferritin induced cytotoxicity 
(Figure 3A). This divergent effect could be explained by 
the pH-dependent H-ferritin release of iron at the level of 
late endosomes, i.e. the neutralization of endosomal pH 
induced by CHL increases the iron retention by H-ferritin. 
The not-yet biomineralized iron could be released more 
easily upon acidification (Figure 4A) from the protein sites 
in the ferroxidase site, where the coordination sites are 
mainly provided by carboxylate and imidazole side chains. 
The redox activity, as measured by cytoplasmatic ROS 
generation, is only modestly increased from the apo- to 
the iron-loaded proteins and the increase is actually more 
modest for H than for L. We conclude that iron toxicity is 
only marginally dependent on ROS generation.
The apparent H paradox 
Our present findings rise an obvious question. Why 
a human protein is toxic for human cells? Here we have 
to consider a few key aspects: i) Endogenous ferritin is 
a cytoplasmic protein; under the cytosolic pH its cargo 
is stable and is not readily released [34]. ii) The natural 
cytoplasmic ferritin never undergoes endosomal-mediated 
import with consequent iron release induced by the low 
pH in endosome. iii) Only ferritin that could be externally 
administered via the blood stream can be internalized via 
TfR-1 receptors leading to endosomal internalization.
The expression of TfR1 on tumor cells is accounted 
for in terms of the needs for the fast growing tumor cells 
to import sufficient iron for the set-up of fundamental 
biological functions. However, when H-ferritin is involved 
in place of transferrin, the iron uptake may overcome 
the physiological needs and the toxic role of redox iron 
center come to prevail. The observed behavior may be 
accounted for in terms of the set-up of a spontaneous cell 
death process induced by iron-loaded H-ferritin taken up 
through TfR1 receptors. 
In summary, the toxicity of iron-loaded H-ferritin 
is due to two main factors: the presence of a mobile iron 
pool, which has no counterpart in HoS-ferritins, and the 
lability of this pool at the low pH encountered during 
the endosomal import. On this basis, the exploitation of 
H-ferritins pro-toxic properties may open new horizons 
in the field of novel cancer therapies based on an iron 
dependent-mechanism that leads to cell death. 
MATERIALS AND METHODS
Apoferritin and iron-loaded ferritin from equine 
spleen (reported to contain > 90% of L subunits), Thiazolyl 
Blue Tetrazolium Bromide, DCF-DA, deferoxamine 
mesylate, chloroquine and all other chemicals were 
purchased from Sigma-Aldrich (St Louis, MO). The 
apo- and iron-loaded ferritin samples were used without 
any further purification and, given their composition, are 
hereafter named HoS−Apo and HoS−1000. The number 
of Fe/cage in iron-loaded HoS-ferritin was measured by 
ICP-MS.
H-ferritin production/purification
The gene-coding sequence for human H-ferritin 
was custom-synthesized (GenScript, USA) and subcloned 
into pET-9a expression vector using NdeI and BamHI 
restriction sites. The expression plasmid was introduced by 
thermal shock into E. coli strain BL21 (DE3) pLysS cells. 
Transformants were selected in LB agar supplemented 
with 50 mg L-1 kanamycin. Cells were grown at 37° C 
until A600 nm reached 0.6−0.8, and subsequently induced 
with isopropyl 1-thio-β-D-galactopyranoside (IPTG, 1 
mM final concentration) for 4 h. Human H-ferritin was 
purified from the harvested cells, as described previously 
[4, 18]. Briefly, cells were broken by sonication and the 
cell free extract obtained after centrifugation (40 min, 
40,000 rpm, 4° C) was incubated for 15 min at 65° C as 
the first purification step. After removal of the aggregated 
proteins (15 min, 40,000 rpm, 4° C), the supernatant 
solution was dialyzed against 20 mM Tris-HCl pH 7.5; 
applied to a Q-Sepharose column in the same buffer and 
eluted with a linear 0−1 M NaCl gradient in 20 mM Tris-
HCl pH 7.5. Fractions containing ferritin, identified by 
Coomassie staining of SDS-PAGE gels, were combined 
and further purified by size exclusion chromatography 
using a Superdex 200 16/60 column. (GE Healthcare Life 
Sciences) Iron and other metal ions present in the purified 
ferritin were removed by four dialysis steps overday and at 
4° C overnight, each using 4 L 20 mM Tris-HCl, 2.5 mM 
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EDTA, 10 mL ammonium thioglycolate pH 7.5 to reduce 
and chelate the iron, followed by four dialysis steps at 
room temperature each using 4 L 20 mM Tris-HCl, pH 7.5.
Preparation of iron-loaded H-ferritin and HoS−
ferritin 
Iron loading into human recombinant H-apoferritin 
homopolymer (100% H chain) and HoS−Apo from equine 
spleen was carried out by adding a FeSO4 solution (200 
mM in 1 mM HCl at protein/Fe ratio of 1:500 and 30 
mM in 1 mM HCl at protein/Fe ratio of 1:75) to a 4.5 
µM protein solution dissolved in 100 mM MOPS, 100 
mM NaCl pH 7 buffer. After the addition of the iron salt, 
the sample was vigorously vortexed for 5 sec, then left 
at 25° C for 2 hours and at 4° C overnight. The iron-
loaded H-ferritin and HoS−ferritin were then purified 
by two cycle of dialysis at 4° C using 1 L of 4 mM 
Hepes, 150 mM NaCl pH 7.4 as external buffer. Final 
iron concentration was measured by ICP-MS. Samples 
of H-ferritin and HoS−ferritin were loaded with about 
350 (H-350 and HoS−350) and 50 (H-50 and HoS−50) 
Fe/cage. The protein concentration was measured by the 
Bradford assay using Bovine Serum Albumin (BSA) as a 
standard. 
ICP-MS 
Iron concentration was determined by using 
inductively coupled plasma mass spectrometry (ICP-MS; 
element-2; Thermo-Finnigan, Rodano (MI), Italy). Sample 
digestion was performed with concentrated HNO3 (70%, 
1 mL) under microwave heating at 160° C for 8 minutes 
(Milestone MicroSYNTH Microwave labstation). 
NMRD profiles 
The 1/T1 nuclear magnetic relaxation dispersion 
profiles (NMRD) of water protons were measured over 
a continuum of magnetic field strengths from 0.00024 
to 0.5 T (corresponding to 0.01–20 MHz proton Larmor 
frequency) on a Fast Field Cycling relaxometer (Stelar 
Spinmaster FFC 2000 relaxometer) equipped with a 
resistive low inductance air cored silver solenoid [35]. The 
relaxometer operates under complete computer control 
with an absolute uncertainty in the 1/T1 values of ± 1%. 
The typical field sequences used were the NP sequence 
between 20 and 8 MHz and the PP sequence between 8 
and 0.01 MHz. The observation field was set at 16 MHz. 
T1 was determined by the saturation recovery method. 16 
values of delay (t) between pulses were used. The number 
of averaged experiments was 2. 
HeLa cell line 
Cervical carcinoma (HeLa) cell line was obtained 
from the American Type Culture Corporation. They were 
cultured in RPMI 1640 medium (Lonza) containing 
10% (v/v) fetal bovine serum (FBS), 2 mM glutamine, 
100 U/ml penicillin, and 100 U/ml streptomycin. Cells 
were incubated at 37° C in a humidified atmosphere of 
5% CO2. The cell line was routinely tested to make sure of 
the absence of mycoplasma contamination (MycoAlert™ 
PLUS Mycoplasma Detection Kit, Lonza).
Uptake experiments 
For uptake experiments, HeLa cells were seeded at 
a density of 2.5 × 105 cells in a 25 cm3 culture flask and 
placed in a wet (37° C) 5% CO2 air atmosphere incubator. 
At 24 h post seeding, cells were incubated with increasing 
concentrations of the above-mentioned H−350, HoS−350 
or HoS−1000. After 24 h of incubation, cells were washed 
three times with 10 mL ice-cold PBS, detached with 
trypsin/EDTA and sonicated for 30″ at 30% power in ice. 
The Fe content was determined by ICP-MS. The protein 
concentration (proportional to the cell number) was 
determined from cell lysates by the Bradford assay, using 
BSA as a standard.
Proliferation assay 
For proliferation assay, Hela cells were seeded 
at a density of 4 × 104 cells in a 3.5 cm diameter petri 
dishes and placed in a wet (37° C) 5% CO2 air atmosphere 
incubator. At 24 h post seeding, four dishes were 
incubated with H−50 (0.5 µM) or H−350 (0.5 µM) or 
HoS−1000 (3 µM) for 24 h. Untreated cells were used as 
a control. At the end of the incubation, they were washed 
three times with 10 mL ice-cold PBS and only a dish for 
each incubated ferritins, detached with trypsin/EDTA, 
sonicated and transferred into falcon tubes. Then, cells 
were sonicated and the protein concentration (proportional 
to the cell number) from cell lysates was determined by 
the Bradford method. The remaining dishes were leaved in 
cell incubator at 37° C and 5% CO2, detached with trypsin/
EDTA at day 2,3 and 5 post incubation and their protein 
concentration was determined.
Competition assays
To demonstrate that the uptake of H−350 involves 
TfR1 and in order to assess whether the presence of 10% 
of H-chains in HoS-ferritin can mediate its uptake through 
H-Ferritin receptors competition assays was carried out. 
Hela cells were seeded at a density of 2.5 × 105 in a 6 cm 
diameter petri dishes and placed in a wet (37° C) 5% CO2 
air atmosphere incubator. At 24 h post seeding, H−350 
(1 µM) and HoS−1000 (1 µM) were incubated in the 
presence of Holo transferrin human (Sigma) 20 µM for 5 
hours. Moreover, to demonstrate that the uptake of HoS−
Ferritin involves SCARA5 receptors, 24 h post seeding, 
Hela cells were incubated with HoS-1000 (0.5 µM) for 
5 h in the presence of 5 µg/mL anti−SCARA5 antibody 
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(abcam ab118894) blocking the receptor. The competitions 
were evaluated by measuring Fe content by ICP−MS of 
cell lysates with respect to H−350 or HoS−1000 incubated 
in the same condition without the presence of competitor. 
FACS analysis of Transferrin Receptor 
expression
 In order to perform FACS (Fluorescence Activated 
Cell Sorting) analysis, 2 × 105 Hela cells were seeded in 
3.5 cm of diameter culture dishes. The day after, cells 
were treated for 24 h with 0.34 mM Fe(III) citrate (Sigma 
Aldrich), 20 µM human Holo−transferrin (Sigma Aldrich) 
or 1 µM H−50 or 1 µM H-350. For the experiment, cells 
were grown in RPMI medium (Lonza). At the end of the 
incubation, the medium was removed and the cells were 
washed three times with PBS. Then, they were treated with 
a non-enzymatic dissociation solution (Sigma Aldrich) for 
15 min at 37° C, transferred in 15 ml falcon tubes and 
counted in PBS. Cell number was determined using a cell 
sorting chamber (Burker-Turk chamber). The cells were 
divided in falcon tubes containing 1 × 106 cells for each 
one. 
All samples were centrifuged (1100 rpm for 5’), the 
PBS was removed, and the cells were further washed with 
PBS and centrifuged (1100 rpm for 5’). All the samples 
were incubated in 10% FBS (0.5 ml) for 30’ at 4° C, 
spun down (1100 rpm for 5’) and washed twice with PBS 
(3 ml). The PE conjugated antibody (mAb anti human 
CD71, BD Pharmingen) selective for TfR1 was added to 
the samples previously described (20 μl in 100 ul of 0.1% 
BSA/PBS) and to a non-treated sample of Hela cells. As 
a negative control, a mouse isotype control antibody PE-
conjugated (Miltenyi Biotec) (5 ul in 100 μl of 0.1% BSA/
PBS) was incubated to a non-treated sample of Hela cells. 
The incubation was performed at 4° C for 40’. All samples 
were washed with PBS (2 × 3 ml) and centrifuged (1100 
rpm for 5’). Finally, cells were diluted in PBS (250 μl) and 
evaluated for their PE fluorescence on a flow cytometer 
(Becton Dickinson, FACS Calibur). Their PE fluorescence 
was analyzed using the CELLQUEST PRO program: the 
mean fluorescence intensity of the treated samples has 
been calculated as a percentage with respect to the non-
treated Hela cells. 
MTT assay
MTT assay is based on the tetrazolium salts 
reduction to formazan by mitochondrial succinate 
dehydrogenase (SDH), which is quantified 
spectrophotometrically. 5 × 103 Hela cells were seeded 
in a 96-well microtiter plate at 37° C and 5% CO2 air 
atmosphere. 24 h later, the cells were incubated for 24 h at 
37° C and 5% CO2 with increasing concentration of H-50, 
H−350, HoS-50, HoS-350 and HoS−1000 and H- and 
HoS-apoferritin. Furthermore, H-350 (0.5 µM) and HoS-
1000 (2.5 µM) were also incubated in absence or in the 
presence of DFO mesylate (150 µM) or chloroquine (100 
µM) for 24 h. After this time, the medium was removed 
and 100 µl of Thiazolyl Blue Tetrazolium Bromide 
dissolved in medium at the concentration of 0.45 mg/mL 
was added into each well and the plate was incubated for 
4 h at 37° C and 5% CO2. Then, the medium was removed, 
150 µl of DMSO were added into each well to solubilize 
the formazan salt crystals produced by the metabolism 
of live cells and the microplate was incubated at room 
temperature for 30 minutes. Finally, absorbance was 
read at 570 nm with iMark microplate reader (Biorad). 
Cell viability was reported as percentage of death cells 
observed in treated samples relative to that observed in 
control cells. The experiment was performed in triplicate 
and the data were graphically presented as mean ± SD.
Iron(II) mobilization from H- and HoS- ferritin
Iron loaded H- and HoS- ferritin (0.4 µM) have been 
incubated up to 3 h at 25° C in different buffers (Hepes/
NaCl pH 7.4; 0.1 M acetate buffer pH 5) in the presence 
of 1 mM 2,2′-bipyridine under aerobic conditions. 
Incubations of proteins in Hepes/NaCl buffer at pH = 
7.4 have been repeated in the presence of glutathione 
(0.25 mM) or ascorbate (0.25 mM) and of 1 mM 
2,2′-bipyridine. The concentration of the reductively 
mobilized iron cations from ferritin was measured by 
following the absorption of the Fe(II)–bipyridine complex 
at 530 nm (ε = 8650 M−1 cm−1).
Iron(III) mobilization from H− and HoS− 
ferritin
Iron loaded H- and HoS- ferritin (0.4 µM) have 
been incubated up to 3 h at 25° C in different buffers 
(Hepes/NaCl pH 7.4; 0.1 M acetate buffer pH 5) in the 
presence of 0.25 mM xylenol orange (Sigma) under 
aerobic conditions. At different time intervals the solutions 
have been centrifuged by vivaspin filters (50000 MW 
cut−off) (Sartorius) and 100 μl of the filtered solutions 
were taken to measure Fe(III) concentration after adding 
700 μl of xylenol orange 0.25 mM in 20 mM H2SO4. 
The 100 μl taken were renewed at each time interval. 
The concentration of Fe(III) released from ferritin was 
measured by following the absorption of the Fe(III)–
xylenol orange complex at 560 nm (ε = 1647 M−1 cm−1).
Transmission electron microscopy (TEM) studies 
TEM analysis of H−350, HoS-350 and HoS−1000 
samples (10µM in Hepes/NaCl pH 7.4) was carried out 
using a JEOL JEM-3010, a 300 kV ultrahigh resolution 
analytical Theoretical resolution of 0.17 nm. Electron gun: 
Cool beam LaB6 Equipped with a Gatan US1000 CCD 
camera.
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TEM analysis of HeLa cells was carried out after 
their incubation for 3 h at 37° C with H-350 1 µM or 
HoS-1000 2.5 µM. Control cells were incubated under 
the same conditions without ferritin addition. Cells 
were fixed with 2.5 % glutaraldehyde solution in 
0.1 M phosphate buffer pH 7.4 and post-fixed in osmium 
tetroxide solution. Samples were then dehydrated in 
graded alcohol and embedded under vacuum in Epson 
812. 70 nm slices were sequentially stained with 0.04% 
bismuth subnitrate, saturated uranyl acetate and 0.25% 
lead citrate and viewed with a Jeol 1400 microscopy 
(USA). The latter staining procedure enhances ferritin 
detection [36].
Measurement of reactive oxygen species (ROS) 
production
Intracellular ROS production was detected 
using the non-fluorescent cell permeating compound, 
2’,7’-dichlorodihydro-fluorescein diacetate (DCF-DA). 
In order to evaluate the effect of H- and HoS-ferritin on 
the ROS production, Hela cells were seeded at a density 
of 1 × 105 cells in 3.5 cm—diameter dishes and were 
placed for 24 h in a wet (37° C) 5% CO2 air atmosphere 
incubator. Iron-loaded H- and HoS-ferritins and H- and 
HoS-apoferritins were incubated at protein concentration 
of 5 µM for 24 h at 37° C, 5% CO2. After the incubation, 
cells were washed two times with PBS and incubated 
with 5 µM of DCF-DA for 30’ at 37° C, 5% CO2 in pre-
warmed EBSS buffer. Cells were then washed two times 
with PBS and detached using a cell scraper in 100ul of 
PBS. Cells were sonicated in ice for 5 sec at 30% power 
and the protein content of cells were determined by the 
commercial Bradford method. The fluorescence of cells 
lysates was measured using a fluorometer microplate 
reader Promega Glomax-multi detection system (Promega 
Corporation, 2800 Woods Hollow Road Madison, WI 
53711 USA) using a blue module (ex 490 nm, em 510-570 
nm) on samples containing 10 µg of cell proteins in 200 µl 
of PBS. The fluorescence intensity of iron loaded H− and 
HoS− ferritins and H− and HoS− apoferritins cells lysates 
samples was calculated as a percentage with respect to the 
fluorescence intensity values of untreated cells used as a 
control. 
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